The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin
Open accessAbstract
BACKGROUND: Ankylosing spondylitis (AS) shares many characteristics with inflammatory bowel disease (IBD). Intestinal microbiota most likely plays an important role in the development of IBDs and may also be involved in the pathogenesis of AS. We aimed to define and compare the fecal microbiota composition in patients with AS, ulcerative colitis (UC), and healthy controls (HC) and to determine relationships between fecal microbiota, fecal calprotectin, and disease-related variables in AS. METHODS: Fecal microbiota composition was assessed with GA-map™ Dysbiosis Test (Genetic Analysis, Oslo, Norway), which also reports the degree of deviation of the microbiota composition compared with a healthy control population, a Dysbiosis Index (DI) score 1-5. The AS patients were assessed with questionnaires, back mobility tests, fecal calprotectin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). RESULTS: Totally, 150 patients with AS (55% men, median age 55.5 years, median BASDAI 3.2), 18 patients with UC (56% men, median age 30.5 years), and 17 HC (65% men, median age 22 years) were included. Principal component analysis showed highly separate clustering of fecal microbiota from the patients with AS, UC, and HC. Compared with HC, fecal microbiota in AS was characterized by a higher abundance of Proteobacteria, Enterobacteriaceae, Bacilli, Streptococcus species, and Actinobacteria, but lower abundance of Bacteroides and Lachnospiraceae. Further, fecal microbiota composition differed between patients with normal (≤ 50 mg/kg, n = 57) and increased (≥ 200 mg/kg, n = 36) fecal calprotectin. Patients with increased fecal calprotectin had lower abundance of bacteria with anti-inflammatory properties such as Faecalibacterium prausnitzii and Clostridium and higher abundance of the genus Streptococcus. No association was found between the fecal microbiota composition and HLAB27 status, disease activity, function, or medication. Dysbiosis (defined as DI ≥ 3) was found in 87% of AS patients. CONCLUSIONS: Patients with AS have a distinct fecal microbiota signature, which is linked to fecal calprotectin levels, a marker of intestinal inflammation, but not to other clinical parameters. These findings suggest a local interplay between intestinal microbiota and gut inflammation in AS. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00858819. Registered March 9, 2009.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
van der Linden, S., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,707
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Satsangi, J., Silverberg, M. S., Vermeire, S., & Colombel, J.-F. (2006) · Gut · doi:10.1136/gut.2005.082909 · Cited by 3,173
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,037
The Microbiome in Inflammatory Bowel Disease: Current Status and the Future Ahead
Kostic, A. D., Xavier, R. J., & Gevers, D. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.009 · Cited by 1,789
Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos‐Vargas, R., Dougados, M., Hermann, K., Landewé, R., Maksymowych, W. P., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104018 · Cited by 1,654
Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C., Glasser, A.-L., Barnich, N., Bringer, M.-A., Swidsinski, A., Beaugerie, L., & Colombel, J.-F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.061 · Cited by 1,566
Gut microbiota in the pathogenesis of inflammatory bowel disease
Nishida, A., Inoüe, R., Inatomi, O., Bamba, S., Naito, Y., & Andoh, A. (2017) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-017-0813-5 · Cited by 1,440
Proteobacteria: A Common Factor in Human Diseases
Rizzatti, G., Lopetuso, L. R., Gibiino, G., Binda, C., & Gasbarrini, A. (2017) · BioMed Research International · doi:10.1155/2017/9351507 · Cited by 1,308
Research works printed but not linked: 1
- Eriksson LK-WN, Trygg J, Wikström C. Multi- and megavariate data analysis: part I: basic principles and applications. Umeå: Umetrics Inc; 2006.
Cited by
Sorted by citations
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?
Mauro, D., Thomas, R., Guggino, G., Lories, R. J. U., Brown, M. A., & Ciccia, F. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00625-y · Cited by 371
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Ankylosing spondylitis risk factors: a systematic literature review
Hwang, M. C., Ridley, L. K., & Reveille, J. D. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05679-7 · Cited by 164
Yang, M., Wan, X., Zheng, H., Xu, K., Xie, J., Yu, H., Wang, J., & Xu, P. (2023) · Nutrients · doi:10.3390/nu15041057 · Cited by 125
Gut microbiome studies in CKD: opportunities, pitfalls and therapeutic potential
Krukowski, H., Valkenburg, S., Madella, A. M., Garssen, J., van Bergenhenegouwen, J., Overbeek, S. A., Huys, G. R. B., Raes, J., & Glorieux, G. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00647-z · Cited by 127
Metadata
- Authors
- Klingberg, E., Magnusson, M. K., Strid, H., Deminger, A., Ståhl, A., Sundin, J., Simrén, M., Carlsten, H., Öhman, L., & Forsblad-d’Elia, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
- Södra Älvsborg Hospital (SE)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Klingberg, Eva
- ORCID
- Venue
- Arthritis Research & Therapy
- Published
- 2019-11-27
- Volume
- 21
- Issue
- 1
- Pages
- 248-248
- ISSN
- 1478-6354 (ISSN-L)
- 1478-6362
- PMC
- PMC6880506
- OpenAlex
- W2990319014
- Cited by
- 101
- References
- 52
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 13 · 2023: 16 · 2022: 22 · 2021: 16 · 2020: 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DiVA at Umeå University (Umeå University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Swedish state under the agreement between the Swedish Government and the county councils, the ALF-agreement (ALFGBG-64220)
- The Swedish state under the agreement between the Swedish Government and the county councils, the ALF-agreement (ALFGBG-825511)
- Västra Götalandsregionen (VGFOUREG-383071)
- Rune och Ulla Amlövs Stiftelse för Neurologisk och Reumatologisk Forskning (.)
- Reumatikerdistriktet i Göteborg (.)
- Göteborgs Läkaresällskap (.)
- COMBINE (.)
- Stiftelsen Reuma Forskningsfond Margareta (.)
- Svenska Läkaresällskapet (SLS-409021)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- ankylosing spondylitis, gut microbiota, fecal calprotectin, dysbiosis, ulcerative colitis, inflammatory bowel disease, Proteobacteria, Enterobacteriaceae, Streptococcus, Faecalibacterium prausnitzii, Clostridium, Lachnospiraceae, Bacteroides, HLA-B27
- MeSH terms
- Gastrointestinal Microbiome, Adult, Bacteria, C-Reactive Protein, Colitis, Ulcerative, Feces, Female, Humans, Male, Middle Aged, Population Dynamics, Surveys and Questionnaires, Spondylitis, Ankylosing, Leukocyte L1 Antigen Complex, Young Adult, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review